company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,175504000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,175504000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,159818000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,101290000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,516912000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4324000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,622526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-462708000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,13471000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,16328000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2857000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-459851000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-459851000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-459851000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-459851000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,140556000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,140556000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,140600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2008.0,FY,2008-01-01,2008-12-31,2011-02-17 16:37:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33889000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33889000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3647000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3647000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,30242000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,32574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,135230000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,176961000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-146719000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,327000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1847000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11925000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-158644000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,173259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,173259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,173100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q4,2009-10-01,2009-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,101889000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,101889000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14202000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14202000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,87687000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,130192000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,550274000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,14033000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,701699000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-614012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,31329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5010000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1847000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-28166000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-642178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-642178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-642178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-642178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,173259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.71
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,173259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.71
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,173100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,FY,2009-01-01,2009-12-31,2012-02-22 17:08:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.71
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,68000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,68000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,10555000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,10555000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,57445000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,97618000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,415044000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,12076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,524738000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-467293000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20924000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4683000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16241000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-483534000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-483534000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-483534000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-483534000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,178735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,178735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,178100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3YTD,2009-01-01,2009-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21245000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,36572000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,132132000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,774000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,169478000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-148233000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1927000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1332000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-149565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,178735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,178735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,178100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q3,2009-07-01,2009-09-30,2010-10-28 16:53:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,43043000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,43043000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6843000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6843000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,61046000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,282912000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,11302000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,355260000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-319060000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18997000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4088000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14909000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-333969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-333969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-333969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-333969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,172563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,172563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,173000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2YTD,2009-01-01,2009-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19064000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19064000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15797000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,32526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,139331000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1107000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,172964000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-157167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15619000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1489000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14130000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-171297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,172563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,172563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,173000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q2,2009-04-01,2009-06-30,2010-08-03 16:41:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23979000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23979000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3576000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3576000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20403000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28520000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,143581000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,10195000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,182296000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-161893000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3378000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2599000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-779000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-162672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,155860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,155860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,156400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2009.0,Q1,2009-01-01,2009-03-31,2010-05-03 16:33:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,65524000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,65524000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3049000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3049000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,62475000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,62478000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,168888000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-2257000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,229109000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-166634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,523000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-6595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-13758000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-180392000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q4,2010-10-01,2010-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,143370000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,143370000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12730000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12730000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,130640000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,187800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,637416000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1501000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,826717000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-696077000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,19275000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1955000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-41229000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-58549000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-754626000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-754626000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-754626000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-754626000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.77
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.77
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,FY,2010-01-01,2010-12-31,2013-03-01 16:01:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.77
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,77846000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,77846000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9681000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9681000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,68165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,125322000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,468528000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,3758000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,597608000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-529443000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11589000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1432000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-34634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-44791000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-574234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-574234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-574234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-574234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3YTD,2010-01-01,2010-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,111735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,111735000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13328000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13328000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,98407000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,157896000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,603758000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,5715000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,774569000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-676162000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21994000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1759000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-36481000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-56716000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-732878000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-732878000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-732878000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-732878000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.71
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.71
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3TTM,2009-10-01,2010-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.71
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23795000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23795000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3228000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3228000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20567000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,48855000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,170434000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,866000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,220155000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-199588000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3951000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5911000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9369000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-208957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q3,2010-07-01,2010-09-30,2011-11-03 17:16:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,54051000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,54051000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6453000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6453000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,47598000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,76467000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,298094000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2892000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,377453000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-329855000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7638000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,939000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-28723000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-35422000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-365277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-365277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-365277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-365277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2YTD,2010-01-01,2010-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,112897000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,112897000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13812000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13812000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,99085000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,145613000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,565456000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,5623000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,723892000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-624807000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,19970000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1861000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-30570000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-48679000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-673486000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-673486000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-673486000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-673486000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2TTM,2009-07-01,2010-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31622000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31622000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3086000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3086000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,28536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40915000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,155082000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2112000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,198109000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-169573000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3683000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,484000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-30433000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-200006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200397000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q2,2010-04-01,2010-06-30,2011-08-09 16:13:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,100339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,100339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,13993000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,13993000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,86346000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,137224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,549705000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4618000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,698747000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-612401000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,31906000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2866000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3336000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-32376000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-644777000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-644777000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-644777000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-644777000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,198935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,198935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,199100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1TTM,2009-04-01,2010-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22429000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22429000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3367000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3367000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19062000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,35552000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,143012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,780000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,179344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-160282000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3955000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,455000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1489000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4989000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-165271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,198935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,198935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,199100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2010.0,Q1,2010-01-01,2010-03-31,2011-05-06 16:18:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,563340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,563340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,30127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,30127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,533213000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,121881000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,186438000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,992000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,309311000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,223902000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-26022000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-39362000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,239000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-13101000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,210801000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22660000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,188141000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,188141000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,29512000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,158629000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204891000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,208807000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.84
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,211200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1410626000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1410626000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,80505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,80505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1330121000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,400721000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,707706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,105800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2074000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1216301000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,113820000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-37681000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-15694000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-53375000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,60445000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,19266000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,41179000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,41179000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,11605000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,29574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204891000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,208807000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,211200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,FY,2011-01-01,2011-12-31,2014-02-11 16:38:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,847286000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,847286000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,50378000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,50378000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,796908000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,278840000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,521268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,105800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1082000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,906990000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-110082000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,26022000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1681000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-15933000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-40274000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-150356000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3394000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-146962000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-146962000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-17907000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-129055000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,206002000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.66
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219349000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.7
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,208600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3YTD,2011-01-01,2011-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.66
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,912810000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,912810000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,53427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,53427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,859383000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,341318000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,690156000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,105800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-1175000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1136099000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-276716000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,33708000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2204000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-22528000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-54032000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-330748000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3394000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-327354000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-327354000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-17907000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-309447000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,206002000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.56
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219349000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.6
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,208600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3TTM,2010-10-01,2011-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.56
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,659200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,659200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,38406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,38406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,620794000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,110654000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,189052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,105800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-419000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,405087000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,215707000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7059000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,77000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-8115000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-15097000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,200610000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-27842000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,228452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,228452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,7342000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,221110000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,206002000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219349000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.02
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,208600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 16:32:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,188086000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,188086000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11972000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11972000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,176114000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,168186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,332216000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1501000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,501903000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-325789000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18963000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1604000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-7818000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-25177000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-350966000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,24448000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-375414000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-375414000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-350165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,204800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2YTD,2011-01-01,2011-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,277405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,277405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,259156000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,279519000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,671538000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,110000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,951167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-692011000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,30600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2620000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-20324000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-48304000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-740315000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,24448000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-764763000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-764763000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-739514000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.66
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.66
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,204800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2TTM,2010-07-01,2011-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.66
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,114424000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,114424000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,9306000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,9306000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,105118000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,96663000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,173604000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,271008000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-165890000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6962000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,202000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2220000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8980000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-174870000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,24448000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-199318000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-199318000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-174069000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,204413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,204800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:31:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,194603000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,194603000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12029000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12029000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,182574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,223771000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,653016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1481000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,878268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-695694000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,27321000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2902000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-45338000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-69757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-765451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-765451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-765451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-765451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,202329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.81
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,202329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.81
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,202400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1TTM,2010-04-01,2011-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.81
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,73662000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,73662000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2666000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2666000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,70996000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,71523000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,158612000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,760000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,230895000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-159899000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12001000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5598000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16197000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-176096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,202329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,202329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,202400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2011.0,Q1,2011-01-01,2011-03-31,2012-05-10 16:17:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.87
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,333994000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,333994000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,87715000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,87715000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,246279000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,106337000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,172829000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,194000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,279360000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33081000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-15040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,11726000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3314000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-36395000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-41725000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5330000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-83406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-78076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1928000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-76148000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,211946000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.36
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,215262000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.35
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,214100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1527042000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1527042000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,279885000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,279885000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1247157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,432681000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,765905000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1844000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1200430000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,46727000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-15040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,309000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14731000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,31996000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-275000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,32271000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-83406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-51135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,55897000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-107032000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,211946000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,215262000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,214100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,FY,2012-01-01,2012-12-31,2015-02-13 16:23:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1193048000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1193048000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,192170000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,192170000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1000878000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,326344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,593076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1650000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,921070000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,79808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11417000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11417000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,68391000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,41450000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,26941000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,26941000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,57825000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30884000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,213100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3YTD,2012-01-01,2012-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1756388000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1756388000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,222297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,222297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1534091000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,448225000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,779514000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2642000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1230381000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,303710000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-26022000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-39362000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-24518000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,279192000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,64110000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,215082000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,215082000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,87337000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,127745000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.66
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.69
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,213100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3TTM,2011-10-01,2012-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.66
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,336006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,336006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,38536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,38536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,297470000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,97684000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,200161000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,696000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,298541000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1071000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-4041000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4041000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5112000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,21355000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26467000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26467000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,31076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-57543000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,213767000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,213100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 16:22:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,857042000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,857042000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,153634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,153634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,703408000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,228660000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,392915000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,954000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,622529000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,80879000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-7376000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7376000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,73503000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20095000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,53408000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,53408000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,26749000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,26659000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.12
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,209500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2YTD,2012-01-01,2012-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2079582000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2079582000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,222167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,222167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1857415000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,461195000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,768405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,105800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1527000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1336927000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,520488000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-18963000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-39285000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-15252000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-35574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,484914000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,14913000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,470001000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,470001000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,63603000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,406398000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.98
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,209500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2TTM,2011-07-01,2012-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,418305000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,418305000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,114423000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,114423000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,303882000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,117514000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,196544000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,594000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,314652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10770000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20063000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34468000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34468000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,30463000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-64931000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,211344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,209500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:02:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1775701000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1775701000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,117050000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,117050000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1658651000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,440344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,745465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,105800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1674000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1293283000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,365368000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-12001000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-39083000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-13837000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-40919000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,324449000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,19298000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,305151000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,305151000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,7891000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,297260000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,208018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.45
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.44
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,208200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1TTM,2011-04-01,2012-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.45
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,438737000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,438737000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,39211000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,39211000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,399526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,111146000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,196371000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,360000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,307877000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,91649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,87908000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,32000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,87876000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,87876000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-3714000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,91590000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,208018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.44
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,219264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,208200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:33:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.44
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1211975000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1211975000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,130277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,130277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1081698000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,356188000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,882097000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,40521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1691706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-610008000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-22926000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,6890000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16036000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-626044000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-122422000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-503622000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-183928000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,242522000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-445028000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-445028000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,224906000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.98
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,224906000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.98
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,224800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,FY,2013-01-01,2013-12-31,2016-02-16 16:23:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.98
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,351157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,351157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,22264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,22264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,328893000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,70361000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,222105000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,27658000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,320124000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8769000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-10111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-22926000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3353000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9462000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-693000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-181251000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,242522000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,53443000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,9158000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,44285000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,224906000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.25
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,224906000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.25
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,224800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.25
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,860818000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,860818000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,108013000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,108013000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,752805000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,285827000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,659992000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,12863000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1371582000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-618777000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-625351000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-129557000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-495794000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-2677000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-498471000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-9158000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-489313000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.23
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.23
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,229900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3YTD,2013-01-01,2013-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.23
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1194812000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1194812000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,195728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,195728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,999084000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,392164000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,832821000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,13057000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1650942000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-651858000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-15040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,15263000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9888000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-661746000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-171282000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-490464000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-86083000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-576547000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-11086000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-565461000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.59
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.58
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,229900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3TTM,2012-10-01,2013-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.59
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,221700000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,221700000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,27339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,27339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,194361000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,86427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,219442000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,12048000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,317917000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-123556000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,95000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4751000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4656000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-118900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2555000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-121455000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-2677000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-124132000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-124132000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,230505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,229900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 16:02:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,639118000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,639118000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,80674000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,80674000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,558444000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,199400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,440550000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,815000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1053665000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-495221000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1214000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11230000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-506451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-132112000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-374339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-374339000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-9158000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-365181000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.69
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.69
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,219900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2YTD,2013-01-01,2013-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.69
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1309118000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1309118000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,206925000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,206925000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1102193000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,403421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,813540000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1705000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1631566000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-529373000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-15040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,6471000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-18585000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-547958000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-152482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-395476000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-83406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-478882000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,19990000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-498872000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.32
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,219900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2TTM,2012-07-01,2013-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.32
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,310750000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,310750000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,37931000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,37931000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,272819000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,106521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,222455000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,776000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,329752000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-56933000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6551000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6578000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-63511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-61712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-61712000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-4547000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-57165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,222053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,219900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q2,2013-04-01,2013-06-30,2014-07-31 17:08:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1416673000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1416673000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,283417000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,283417000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1133256000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,414414000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,787629000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1523000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1616466000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-483210000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-15040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2863000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-15642000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-498852000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-130620000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-368232000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-83406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-451638000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,55000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-506638000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,215421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.37
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,215421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.36
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,215400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1TTM,2012-04-01,2013-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.37
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,328368000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,328368000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,42743000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,42743000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,285625000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,92879000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,218095000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,412900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,39000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,723913000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-438288000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1187000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-442940000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-130313000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-312627000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-312627000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-4611000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-308016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,215421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,215421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,215400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2013.0,Q1,2013-01-01,2013-03-31,2014-05-05 16:07:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,580415000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,580415000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,60987000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,60987000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,519428000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,305409000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,855506000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,50925000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1211840000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-692412000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-72863000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,30400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-42463000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-734875000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6958000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-741833000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-1824000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,4190000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-738555000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-738555000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,235307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,235307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,235200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,FY,2014-01-01,2014-12-31,2017-02-23 15:18:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.14
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,178987000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,178987000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,14184000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,14184000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,164803000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,75224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,190939000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,40843000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,307006000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-142203000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20384000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3990000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-24374000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-166577000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3419000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-169996000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-170060000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-170060000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,236200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 16:23:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,435859000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,435859000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,46960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,46960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,388899000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,226882000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,654043000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,46761000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,927686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-538787000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,51686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,34192000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-17494000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-556281000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4915000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-561196000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-561899000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-561899000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.4
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.4
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,236200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3YTD,2014-01-01,2014-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.4
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,787016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,787016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,69224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,69224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,717792000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,297243000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,876148000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,74419000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1247810000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-530018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,41575000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-22926000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,37545000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26956000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-556974000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,12050000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-569024000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-181251000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,242522000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-508456000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,9158000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-517614000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.15
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,236137000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.15
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,236200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q3TTM,2013-10-01,2014-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.15
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,138421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,138421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,17300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,17300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,121121000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,77446000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,224487000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-270000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,301663000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-180542000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15585000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,37731000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,22146000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-158396000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,693000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-159089000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-159382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-159382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,234400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 16:16:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,256872000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,256872000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,32776000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,32776000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,224096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,151658000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,463104000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,5918000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,620680000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-396584000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,31302000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,38182000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6880000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-389704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1496000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-391200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-391839000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-391839000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,234400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2YTD,2014-01-01,2014-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,829729000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,829729000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,82379000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,82379000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,747350000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,308446000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,904651000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,45624000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1258721000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-511371000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21286000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-22926000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,46286000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2074000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-509297000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,11186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-520483000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-183928000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,242522000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-462528000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,9158000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-471686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.97
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,233808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.97
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,234400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q2TTM,2013-07-01,2014-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.97
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,118451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,118451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,15476000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,15476000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,102975000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,74212000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,238617000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,6188000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,319017000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-216042000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15717000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-15266000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-231308000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,803000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-232111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-232457000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-232457000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,232887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,232887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,232500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:29:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1002058000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1002058000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,103010000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,103010000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,899048000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,337521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,902619000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,46670000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1286810000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-387762000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12252000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-22926000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,8528000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26650000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-414412000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8694000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-423106000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-183928000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,242522000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-364858000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,4611000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-369469000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,232887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.55
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,232887000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.55
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,232500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2014.0,Q1TTM,2013-04-01,2014-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.55
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1032336000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1032336000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,124512000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,124512000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,907824000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,376575000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,995922000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2206000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1374703000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-466879000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-84206000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-6715000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-90921000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-557800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,30381000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-588181000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-588181000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-31847000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-556334000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,241312000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,241312000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,240800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,FY,2015-01-01,2015-12-31,2018-02-14 18:01:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,417935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,417935000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,63385000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,63385000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,354550000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,96549000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,310181000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1524000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,408254000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-53704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-63552000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-84206000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1690000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-22344000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-76048000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1379000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-74669000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-74669000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-938000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-73731000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,241312000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,241312000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,240800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,309816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,309816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,31960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,31960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,277856000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,99772000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,246284000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1826000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,347882000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-70026000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21134000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1326000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-22460000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-92486000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1330000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-93816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-93816000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,1333000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-95149000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,244000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3,2015-07-01,2015-09-30,2016-10-31 16:48:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,614401000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,614401000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,61127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,61127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,553274000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,280026000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,685741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,682000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,966449000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-413175000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,63552000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5025000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-68577000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-481752000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,31760000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-513512000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-513512000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-30909000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-482603000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,244000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3YTD,2015-01-01,2015-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,758957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,758957000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,75154000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,75154000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,683803000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,358553000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,887204000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4846000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1250603000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-566800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11866000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-72863000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-8817000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-93546000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-660346000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,33803000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-694149000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-1824000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,4190000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-690168000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-30909000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-659259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.74
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,241969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.74
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,244000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q3TTM,2014-10-01,2015-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.74
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,166076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,166076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,16860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,16860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,149216000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,94394000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,223858000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2128000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,320380000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-171164000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1414000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-19697000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-190861000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,30131000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-220992000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-220992000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-32144000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-188848000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.78
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.78
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2,2015-04-01,2015-06-30,2016-08-01 16:51:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.78
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,304585000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,304585000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,29167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,29167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,275418000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,180254000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,439457000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-1144000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,618567000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-343149000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,42418000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3699000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-46117000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-389266000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,30430000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-419696000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-419696000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-32242000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-387454000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.61
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.61
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2YTD,2015-01-01,2015-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.61
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,628128000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,628128000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,57378000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,57378000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,570750000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,334005000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,831859000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,43863000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1209727000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-638977000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11116000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-72863000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11481000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-95460000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-734437000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,35892000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-770329000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-1824000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,4190000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-766412000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-32242000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-734170000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-3.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,240757000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-3.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q2TTM,2014-07-01,2015-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-3.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,600473000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,600473000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,57818000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,57818000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,542655000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,317057000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,832488000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,41465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1191010000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-648355000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5590000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-72863000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,24836000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-53617000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-701972000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6454000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-708426000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-1824000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,4190000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-704802000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-98000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-704704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,239493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.97
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,239493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.97
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,239300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1TTM,2014-04-01,2015-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.97
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,138509000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,138509000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,126202000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,85860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,215599000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-3272000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,298187000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-171985000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,21307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5113000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26420000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-198405000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,299000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-198704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-198704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-98000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-198606000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,239493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,239493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,239300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2015.0,Q1,2015-01-01,2015-03-31,2016-05-03 17:03:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1702177000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1702177000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,210460000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,210460000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1491717000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,432829000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1047690000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1262000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1481781000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9936000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-81432000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4130000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-77302000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-67366000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,16665000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-84031000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-84031000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,28021000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-112052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244685000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.46
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244685000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.46
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,243600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,FY,2016-01-01,2016-12-31,2019-02-13 16:38:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.46
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,458706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,458706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,60482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,60482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,398224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,109908000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,248452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,358584000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,39640000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-60993000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-81432000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1105000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-19334000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,20306000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-7423000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,27729000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,27759000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-5186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,32945000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244685000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244685000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,243600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,413783000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,413783000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,54077000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,54077000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,359706000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,106055000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,272370000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,8000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,378433000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18727000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20140000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-167000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-20307000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-39034000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,503000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-39537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-39537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-696000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-38841000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3,2016-07-01,2016-09-30,2017-10-30 17:15:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1243471000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1243471000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,149978000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,149978000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1093493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,322921000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,799238000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1038000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1123197000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-29704000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,60993000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3025000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-57968000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-87672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,24088000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-111760000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-111790000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,33207000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-144997000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.59
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.59
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3YTD,2016-01-01,2016-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.59
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1661406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1661406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,213363000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,213363000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1448043000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,419470000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1109419000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2562000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1531451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-83408000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-2559000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-84206000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1335000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-80312000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-163720000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22709000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-186429000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-186459000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,32269000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-218728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244920000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,242800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q3TTM,2015-10-01,2016-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.9
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,431608000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,431608000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,45252000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,45252000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,386356000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,111652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,271008000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,343000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,383003000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3353000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20155000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1219000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-21374000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18021000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,18100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36121000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36151000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,28374000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-64525000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 16:23:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,829688000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,829688000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,95901000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,95901000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,733787000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,216866000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,526868000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1030000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,744764000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10977000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,40853000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3192000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-37661000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-48638000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,23585000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-72223000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-72253000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,33903000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-106156000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2YTD,2016-01-01,2016-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.43
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1557439000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1557439000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,191246000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,191246000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1366193000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,413187000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1083333000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4380000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1500900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-134707000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-1565000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-84206000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,176000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-82465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-217172000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,23536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-240708000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-240738000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,34298000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-275036000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,244482000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q2TTM,2015-07-01,2016-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.13
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,398080000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,398080000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,50649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,50649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,347431000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,105214000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,255860000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,687000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,361761000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14330000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,20698000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4411000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16287000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30617000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5485000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-36102000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-36102000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,5529000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-41631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,243831000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,243831000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,244900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1,2016-01-01,2016-03-31,2017-04-28 16:22:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1291907000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1291907000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,162854000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,162854000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1129053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,395929000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1036183000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,6165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1438277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-309224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-609000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-84206000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2809000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-80788000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-390012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,35567000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-425579000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-425579000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-26220000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-399359000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,243831000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.65
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,243831000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.65
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,244900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2016.0,Q1TTM,2015-04-01,2016-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.65
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2488652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2488652000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,275119000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,275119000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2213533000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,496079000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1324625000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,255340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,14246000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2090290000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,123243000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,69298000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,11748000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-81382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-138932000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15689000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-107324000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,91635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,91635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-171849000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,263484000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,248858000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,253225000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,FY,2017-01-01,2017-12-31,2020-02-13 16:48:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,651634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,651634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,84052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,84052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,567582000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,134794000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,306664000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,387000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,441845000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,125737000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,24295000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,11748000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-748000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-13295000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,112442000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10257000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,102185000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,102185000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,1501000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,100684000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,248858000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,253225000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,248600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,578165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,578165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,72874000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,72874000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,505291000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,120710000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,454947000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,255340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,337000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,831334000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-326043000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,13574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-77553000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-91127000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-417170000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-125903000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-291267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-291267000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-188315000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-102952000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,251100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3,2017-07-01,2017-09-30,2018-10-25 16:10:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1837018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1837018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,191067000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,191067000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1645951000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,361285000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1017961000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,255340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,13859000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1648445000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2494000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,45003000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-80634000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-125637000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-128131000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-117581000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10550000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10550000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-173350000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,162800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.67
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.65
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,251100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3YTD,2017-01-01,2017-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.67
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2295724000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2295724000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,251549000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,251549000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2044175000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,471193000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1266413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,255340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,14083000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2007029000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,37146000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-15990000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-81432000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-79529000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-144971000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-107825000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-125004000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,17179000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,17209000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-178536000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,195745000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,250268000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.78
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,251100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q3TTM,2016-10-01,2017-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,544135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,544135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,71205000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,71205000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,472930000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,127249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,289451000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,3523000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,420223000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,52707000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14664000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-17201000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,35506000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4337000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,31169000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,31169000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,13173000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,17996000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,247521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,251635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2,2017-04-01,2017-06-30,2018-07-26 16:08:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.07
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1258853000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1258853000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,118193000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,118193000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1140660000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,240575000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,563014000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,13522000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,817111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,323549000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,31429000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3081000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-34510000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,289039000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8322000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,280717000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,280717000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,14965000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,265752000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,247521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.08
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,251635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2YTD,2017-01-01,2017-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.08
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2131342000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2131342000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,232752000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,232752000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1898590000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,456538000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1083836000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,13754000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1554128000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,344462000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-9424000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-81432000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2143000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-74151000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,270311000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1402000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,268909000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,268939000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,9083000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,259856000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,247521000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.05
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,251635000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q2TTM,2016-07-01,2017-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.05
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,714718000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,714718000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,46988000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,46988000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,667730000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,113326000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,273563000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,9999000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,396888000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,270842000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16765000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-544000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-17309000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,253533000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3985000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,249548000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,249548000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,1792000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,247756000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,246024000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.01
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,248700000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.99
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,245300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 16:36:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.01
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2018815000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2018815000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,206799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,206799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1812016000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,440941000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1065393000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,10574000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1516908000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,295108000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-3933000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-81432000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-825000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-78324000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,216784000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,15165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,201619000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,201619000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,24284000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,177335000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,246024000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,248700000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.7
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,245300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2017.0,Q1TTM,2016-04-01,2017-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.72
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3047597000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3047597000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,409539000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,409539000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2638058000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,557616000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1416476000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,29000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-184000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2002908000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,635150000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,72471000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,38352000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-790000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-34909000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,600241000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1486862000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2087103000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2087103000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-9793000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2096896000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254292000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,8.24
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259185000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,8.09
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,254500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,FY,2018-01-01,2018-12-31,2020-02-13 16:48:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,8.24
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,87595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,87595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,122289000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,122289000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-34694000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,153210000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,437881000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-782511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,29000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-162416000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,127722000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18744000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13971000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-90452000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-95225000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,32497000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1492599000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1525096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1525096000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1550527000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254292000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,6.08
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259185000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,5.98
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,254500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,6.08
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1567046000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1567046000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,111255000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,111255000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1455791000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,137295000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,330510000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,782511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-174000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1250142000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,205649000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18686000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,10543000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-60995000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-69138000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,136511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8055000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,128456000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,128456000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,128746000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254905000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259788000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 16:19:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2960002000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2960002000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,287250000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,287250000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2672752000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,404406000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,978595000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,782511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-188000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2165324000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,507428000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,53727000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,24381000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,89662000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,60316000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,567744000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5737000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,562007000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,562007000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,15628000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,546369000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254905000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259788000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.11
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3YTD,2018-01-01,2018-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.16
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3611636000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3611636000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,371302000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,371302000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3240334000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,539200000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1285259000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,782511000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,199000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2607169000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,633165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,78022000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,36129000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,88914000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,47021000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,680186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,15994000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,664192000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,664192000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,17129000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,647053000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254905000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.55
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259788000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.5
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q3TTM,2017-10-01,2018-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.55
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,752157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,752157000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,104382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,104382000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,647775000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,137303000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,337532000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,62000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,474897000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,172878000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18155000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8049000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,53819000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,43713000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,216591000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10341000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,206250000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,206250000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1110000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,207360000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.82
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,258584000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.8
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 16:20:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.82
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1392956000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1392956000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,175995000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,175995000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1216961000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,267111000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,648085000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-14000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,915182000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,301779000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,35041000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13838000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,150657000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,129454000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,431233000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2318000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,433551000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,433551000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,15928000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,417623000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.65
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,258584000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.61
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2YTD,2018-01-01,2018-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.65
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2622755000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2622755000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,332921000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,332921000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2289834000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,522615000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1409696000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,255340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,710000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2188361000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,101473000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,72910000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,25586000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,72356000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25032000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,126505000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-117964000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,244469000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,244469000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-170886000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,415355000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,254135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.63
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,258584000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.59
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,252900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q2TTM,2017-07-01,2018-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.63
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,640799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,640799000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,71613000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,71613000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,569186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,129808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,310553000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-76000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,440285000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,128901000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,16886000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5789000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,96838000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,85741000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,214642000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-12659000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,227301000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,227301000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,17038000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,210263000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,253231000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,258526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.81
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,253300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1,2018-01-01,2018-03-31,2019-05-01 16:37:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.83
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2414733000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2414733000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,299744000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,299744000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2114989000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,512561000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1361615000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,255340000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4171000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2133687000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18698000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,69419000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,16000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-35882000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-54580000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-123968000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,69388000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,69388000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-156603000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,225991000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,253231000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.88
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,258526000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.86
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,253300000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2018.0,Q1TTM,2017-04-01,2018-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.88
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,463437000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,463437000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,185012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,185012000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,278425000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,195277000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,480011000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-949828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1500000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-273040000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,551465000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14249000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12359000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,127375000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,125485000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,676950000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,93764000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,583186000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,583234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,583234000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260673000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.23
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,256900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.27
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4162821000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4162821000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,547758000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,547758000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3615063000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,658498000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1754540000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,4459000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2417497000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1197566000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,58502000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,63678000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,192177000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,197353000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1394919000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,218109000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1176810000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1176810000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1176810000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,4.58
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260673000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.51
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,256900000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,FY,2019-01-01,2019-12-31,2020-02-13 16:48:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.58
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3699384000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3699384000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,362746000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,362746000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3336638000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,463221000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1274529000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,949828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,2959000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2690537000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,646101000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,44253000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,51319000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,64802000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,71868000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,717969000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,124345000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,593624000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,593576000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,593576000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256946000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260473000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.28
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,261400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3YTD,2019-01-01,2019-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3786979000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3786979000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,485035000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,485035000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3301944000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,616431000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1712410000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,167317000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,29000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,4000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,2959000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2528121000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,773823000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,62997000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,65290000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-25650000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-23357000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,750466000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1368254000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2118720000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2118672000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25421000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2144103000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256946000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,8.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260473000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,8.26
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,261400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3TTM,2018-10-01,2019-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,8.39
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1899656000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1899656000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,131914000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,131914000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1767742000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,159674000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,555948000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,949828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,2959000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1668409000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,99333000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14548000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17628000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-31747000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-28667000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,70666000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,13100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,57566000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,57518000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,57518000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256946000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260473000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.22
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,261400000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 16:19:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,941293000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,941293000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,135740000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,135740000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,805553000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,156502000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,379091000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,535593000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,269960000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14837000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,18076000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,53939000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,57178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,327138000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,59711000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,267427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,267427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,267427000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256154000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259822000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 16:20:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.04
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1799728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1799728000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,230832000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,230832000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1568896000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,303547000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,718581000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,1022128000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,546768000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,29705000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,33691000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,96549000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,100535000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,647303000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,111245000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,536058000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,536058000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,536058000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256154000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.09
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259822000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.06
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2YTD,2019-01-01,2019-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.09
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3454369000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3454369000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,464376000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,464376000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2989993000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,594052000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1486972000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,29000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-170000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2109854000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,880139000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,67135000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,58205000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-54898000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-63828000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,816311000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1373299000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2189610000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2189610000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-25721000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2215331000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,256154000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,8.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,259822000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,8.54
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,257100000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q2TTM,2018-07-01,2019-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,8.68
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,858435000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,858435000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,95092000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,95092000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,763343000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,147045000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,339490000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,486535000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,276808000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14868000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,15615000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,42610000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,43357000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,320165000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,51534000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,268631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,268631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,268631000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,255695000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.05
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260175000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.03
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,255800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 16:37:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.05
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3265233000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3265233000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,433018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,433018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2832215000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,574853000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1445413000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,29000000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-108000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2049158000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,783057000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,70453000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,48178000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-55018000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-77293000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,705764000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1422669000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2128433000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2128433000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-26831000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2155264000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,255695000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,8.46
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,260175000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,8.31
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,255800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2019.0,Q1TTM,2018-04-01,2019-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,8.46
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4819493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4819493000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,615163000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,615163000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4204330000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,693711000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1863578000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,6059000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2563348000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1640982000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,57770000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,60639000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,88437000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,91306000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1732288000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,221356000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1510932000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1510932000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1510932000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,259815000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,5.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,263515000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,5.77
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,259800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1TTM,2019-04-01,2020-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,5.85
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1515107000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1515107000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,162497000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,162497000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1352610000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,182258000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,448528000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,1600000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,632386000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,720224000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,14136000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,12576000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-61130000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-62690000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,657534000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,54781000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,602753000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,602753000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,602753000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,259815000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,2.32
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,263515000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.29
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,259800000.0
Vertex Pharmaceuticals Inc,VRTX,54930015RAQRRZ5ZGJ91,0000875320,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 16:37:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.32
